Clinical Trials
Search our team at AdventHealth Research Institute
-
NCT06745323
A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects with Small Cell Lung Cancer (SCLC) (DeLLphi-309)
This study is currently enrolling.Associated Conditions: ThoracicResearch Area: Clinical Cancer ResearchResearch Location: OrlandoThis study is being done to learn more about tarlatamab in people with Small Cell Lung Cancer (SCLC; a type of fast-growing cancer that forms in tissues of the lung and can spread to other parts of...
-
NCT05671510
PRESERVE-003: Phase 3, Two-stage, Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers that Progressed on PD-1/PD-L1 Inhibitors
This study is currently enrolling.Associated Conditions: ThoracicResearch Area: Clinical Cancer ResearchResearch Location: OrlandoThe main purpose of the study is to determine whether the study drug, ONC-392, is safe and well tolerated, and whether it is effective in treating lung cancer, in comparison with a standard of care...
-
NCT05498428
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer
This study is currently enrolling.Associated Conditions: ThoracicResearch Area: Clinical Cancer ResearchResearch Location: OrlandoThe investigational anti-cancer drugs being studied are called amivantamab (JNJ-61186372) and lazertinib (JNJ-73841937). They are being developed for the treatment of locally advanced or metastatic (i...
-
NCT05211895
A Phase 3, Randomized, Double blind, Placebo controlled, Multicentre, International Study of Durvalumab and Domvanalimab (AB154) as Sequential Therapy in Participants with Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer Whose Disease has not Progressed Following Definitive, Platinum-based Concurrent Chemoradiation Therapy (PACIFIC 8)
This study is currently enrolling.Associated Conditions: ThoracicResearch Area: Clinical Cancer ResearchResearch Location: OrlandoThis study is being carried out in stage III NSCLC which cannot be removed by surgery. In this study, we will identify the effectiveness and safety of a possible treatment combination – durvalumab...
-
NCT05142696
A Phase Ib/II Dose Finding Study Assessing Safety and Efficacy of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Extensive Stage Small Cell Lung Cancer (ES-SCLC) in Combination With Carboplatin, Etoposide, and Atezolizumab in Induction and With Atezolizumab in Maintenance Phase
This study is currently enrolling.Associated Conditions: ThoracicResearch Area: Clinical Cancer ResearchResearch Location: OrlandoThe purpose of this part of the study is to evaluate safety of Lutathera in patients with extensive stage small cell lung cancer (ES-SCLC) and to find the recommended dose of Lutathera in combination...
-
NCT06008093
A Phase IIIb, Randomized, Multicenter, Open-label study, to assess the Efficacy of Durvalumab Plus Tremelimumab Versus Pembrolizumab in Combination with Platinum Based Chemotherapy for First Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients who have Mutations or Co mutations in STK11, KEAP1, or KRAS (TRITON)
This study is currently enrolling.Associated Conditions: ThoracicResearch Area: Clinical Cancer ResearchResearch Location: OrlandoTo assess the efficacy of durvalumab plus tremelimumab plus chemotherapy compared with pembrolizumab plus chemotherapy in terms of OS, in participants with non-squamous histology who have metastatic...